Bittar N, Corder C N, Eich R, McGrew F A, Paulk E A, Zellner S
Section of Cardiology, University of Wisconsin, Madison.
Am J Med. 1987 Dec 21;83(6B):30-3. doi: 10.1016/0002-9343(87)90634-6.
This multicenter study assessed the efficacy of a new formulation of nifedipine in 54 patients with stable angina pectoris receiving beta-blocker therapy. This once-daily preparation of nifedipine was administered in double-blind fashion in doses of 30, 60, and 90 mg. All patients experienced pain-limited exercise at placebo baseline treadmill testing. Eight hours post-dose exercise testing resulted in a significant increase in time to onset of angina for all three dose levels of nifedipine but not for placebo. Exercise testing 24 hours after dosing showed significant improvement in time to angina and total exercise time for patients receiving 60-mg and 90-mg doses but not for the 30-mg or placebo categories. These preliminary results suggest that this new formulation of nifedipine is beneficial when added to stable doses of a beta blocker in patients in whom angina is still exhibited during exercise testing.
这项多中心研究评估了一种新剂型硝苯地平对54例正在接受β受体阻滞剂治疗的稳定型心绞痛患者的疗效。这种每日一次的硝苯地平制剂采用双盲方式给药,剂量分别为30毫克、60毫克和90毫克。所有患者在安慰剂基线跑步机测试中均经历了运动受限性疼痛。给药8小时后的运动测试结果显示,硝苯地平的所有三个剂量水平导致心绞痛发作时间显著延长,而安慰剂组未出现这种情况。给药24小时后的运动测试表明,接受60毫克和90毫克剂量的患者心绞痛发作时间和总运动时间有显著改善,但30毫克剂量组或安慰剂组未出现这种情况。这些初步结果表明,对于在运动测试中仍表现出心绞痛的患者,在稳定剂量的β受体阻滞剂基础上加用这种新剂型的硝苯地平是有益的。